134 related articles for article (PubMed ID: 1537082)
1. Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
Punt CJ; de Mulder PH; Burghouts JT; Wagener DJ
Cancer Chemother Pharmacol; 1992; 29(4):326-8. PubMed ID: 1537082
[TBL] [Abstract][Full Text] [Related]
2. Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.
Punt CJ; de Mulder PH; Burghouts JT; Wagener DJ
Semin Oncol; 1992 Apr; 19(2 Suppl 3):208-10. PubMed ID: 1557649
[TBL] [Abstract][Full Text] [Related]
3. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
[TBL] [Abstract][Full Text] [Related]
4. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
6. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.
Sobrero A; Nobile MT; Guglielmi A; Mori A; Aschele C; Bolli E; Tixi L; Gallo L; Parodi GC; Bruzzi P
Eur J Cancer; 1992; 28A(4-5):850-2. PubMed ID: 1524906
[TBL] [Abstract][Full Text] [Related]
8. Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
Labianca R; Giaccon G; Barni S; Ambrosini G; Iirillo A; Fiorentini G; Duro M; Piazza E; Oliani C; Pancera G
Eur J Cancer; 1994; 30A(11):1611-6. PubMed ID: 7833131
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U
Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711
[TBL] [Abstract][Full Text] [Related]
10. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
Sinnige HA; Buter J; de Vries EG; Uges DR; Roenhorst HW; Verschueren RC; Sleijfer DT; Willemse PH; Mulder NH
Eur J Cancer; 1993; 29A(12):1715-20. PubMed ID: 8398300
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
14. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
[TBL] [Abstract][Full Text] [Related]
15. Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
Brunetti I; Falcone A; Bertuccelli M; Cianci C; Ricci S; Conte PF
Am J Clin Oncol; 1994 Jun; 17(3):210-4. PubMed ID: 8192103
[TBL] [Abstract][Full Text] [Related]
16. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH
Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Pazdur R; Ajani JA; Patt YZ; Gomez J; Bready B; Levin B
Cancer; 1993 Feb; 71(4):1214-8. PubMed ID: 8435795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
